论文部分内容阅读
子宫内膜癌是女性最常见的恶性肿瘤之一,过去的十年,其死亡率明显上升,尤其以发展中国家为甚。二甲双胍作为治疗2型糖尿病的一线药物而被大家了解,目前许多研究提供了二甲双胍抗肿瘤作用的证据,并有学者进行小规模的临床研究表明口服二甲双胍可以提高子宫内膜癌患者的生存率,降低复发风险,这些发现均为临床上治疗子宫内膜癌提供了新的思考方向。本文对二甲双胍与子宫内膜癌生存率之间的关系以及其抗肿瘤作用进行综述。
Endometrial cancer is one of the most common malignancies in women and its mortality has risen markedly in the past decade, especially in developing countries. Metformin as a first-line treatment of type 2 diabetes is well known, many studies provide evidence of the anti-tumor effect of metformin, and some scholars conducted a small-scale clinical studies have shown that oral metformin can improve the survival rate of patients with endometrial cancer, reduce Recurrence risk, these findings provide a new direction for the clinical treatment of endometrial cancer. This article reviews the relationship between metformin and endometrial cancer survival rate and its anti-tumor effect.